• Home
  • Products
  • About
  • Contact

relapsed or refractory dlbcl

Current Location : Home > relapsed or refractory dlbcl

  • Outcomes in refractory diffuse large B-cell lymphoma

    Oct 19 2017 · Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60 to 70 up to 50 of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited.

    Get Price
  • REFERENCESUpToDate

    Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). For patients who are refractory to initial treatment or relapse after an initial response only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy alone 1 .

    Get Price
  • Risk Factors for Early Relapse of DLBCL After CAR-T

    Nov 24 2020 · Vercellino L Di Blasi R Kanoun S et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

    Get Price
  • POLA BR for Relapsed or Refractory DLBCLFull Text View

    Sep 01 2020 · Brief Summary This is a phase II multicenter open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine (B) and rituximab (R) in transplant-eligible patients with relapsed or refractory DLBCL. A total of 22 patients will be enrolled over a period of 2 years through the University of

    Get Price
  • POLA BR for Relapsed or Refractory DLBCLFull Text View

    Sep 01 2020 · Brief Summary This is a phase II multicenter open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine (B) and rituximab (R) in transplant-eligible patients with relapsed or refractory DLBCL

    Get Price
  • MT-3724 for Relapsed or Refractory DLBCL Molecular

    Subjects must have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma/World Health Organization (REAL/WHO) classification. Subjects must have received at least 2 standard of care regimens for NHL treatment. Subjects must have at least one tumor lesion at screening

    Get Price
  • Relapsed/Refractory DLBCL Undergoes Rapid Evolution With

    High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) however CAR T-cell

    Get Price
  • Relapsed/refractory diffuse large B-cell lymphoma

    The clinical approach to relapsed/refractory DLBCL should include high-dose therapy and autologous stem cell transplantation (HD-ASCT) with curative intent in patients without comorbidities. Results from the recently reported CORAL study suggest that patients refractory to rituximab-containing regimens have inferior outcomes with HD-ASCT.

    Get Price
  • CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed

    Jun 26 2020 · The Alexander trial enrolled 23 patients with relapsed refractory or transformed DLBCL who experienced relapse after ≥2 prior lines of therapy or autologous stem cell transplant (ASCT). The median patient age was 57 years (range 28–83 years). The median number of prior therapies was 3 (range 2–10) and 4 patients had a prior ASCT.

    Get Price
  • FDA approves first chemoimmunotherapy regimen for patients

    Efficacy was evaluated in a study of 80 patients with relapsed or refractory DLBCL who were randomized to receive Polivy with BR or BR alone. Efficacy was based on complete response rate and

    Get Price
  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse

    Dec 01 2018 · Abstract Background Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell

    Get Price
  • New drugs for the management of relapsed or refractory

    May 04 2019 · Relapsed and refractory DLBCL standard approaches Other Section The majority of relapses occur within 2 to 3 years from completion of initial treatment although a low incidence of late

    Get Price
  • Polatuzumab Vedotin in Relapsed or Refractory Diffuse

    Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component.

    Get Price
  • XPOVIO® (selinexor) Relapsed or Refractory DLBCL

    XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from follicular lymphoma after at least 2 lines of systemic therapy. These indications are

    Get Price
  • New drugs for the management of relapsed or refractory

    May 04 2019 · Relapsed and refractory DLBCL standard approaches Other Section The majority of relapses occur within 2 to 3 years from completion of initial treatment although a low incidence of late relapse exists (7). Patients with R-CHOP-refractory disease (1 2 8) have a particularly poor prognosis with a median OS of less than a year (913).

    Get Price
  • Diffuse Large B-Cell Lymphoma Relapsed/Refractory

    High-dose chemotherapy followed by stem cell transplantation can be used to treat patients with DLBCL whose disease is refractory or relapsed following initial chemotherapy.

    Get Price
  • Understanding Diffuse Large B-Cell Lymphoma

    with both newly diagnosed and relapsed/refractory DLBCL. Promising therapies in clinical trials being investigated eith er alone or in combination include MOR208 with lenalidomide (Revlimid) histone deacetylase (HDAC) inhibitors with and without B-cell lymphoma 2 (BCL2) inhibitors and Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib.

    Get Price
  • Tafasitamab plus lenalidomide in relapsed or refractory

    Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.

    Get Price
  • Therapeutic Options for Relapsed/Refractory Diffuse Large

    Sep 10 2020 · One of the major breakthroughs in treatment for relapsed/refractory DLBCL has been the development of chimeric antigen receptor (CAR) T-cell therapy. Two products axicabtagene ciloleucel and tisagenlecleucel have been approved for this indication and both have demonstrated high rates of durable responses.

    Get Price
  • Tafasitamab plus lenalidomide in relapsed or refractory

    Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.

    Get Price
  • Polatuzumab Vedotin in Relapsed or Refractory Diffuse

    Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component.

    Get Price
  • XPOVIO® (selinexor) Relapsed or Refractory DLBCL

    to treat adults with certain types of dif‌fuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who have received at least 2 prior

    Get Price
  • XPOVIO® (selinexor) Relapsed or Refractory Multiple Myeloma

    XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from follicular lymphoma after at least 2 lines of systemic therapy. These indications are

    Get Price
  • FDA approves selinexor for relapsed/refractory diffuse

    On June 22 2020 the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell

    Get Price
  • Tafasitamab plus lenalidomide in relapsed or refractory

    Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options.

    Get Price
  • Management of relapsed/refractory DLBCLScienceDirect

    Sep 01 2018 · Several salvage therapy regimens have been explored prior to ASCT. The main results of prospective studies in patients with relapsed/refractory DLBCL and eligible for transplantation are presented in Table 1. In the randomized phase III CORAL trial including 396 DLBCL patients in first relapse R-DHAP (dexamethasone cytarabine and cisplatine) and R-ICE (ifosfamide carboplatine

    Get Price
  • Incidence of relapsed/refractory diffuse large B-cell

    Jan 07 2021 · We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007–2014 to assess treatment intent and risk of relapsed/refractory

    Get Price
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Dec 10 2011 · The clinical approach to relapsed/refractory DLBCL should include high-dose therapy and autologous stem cell transplantation (HD-ASCT) with curative intent in patients without comorbidities. Results from the recently reported CORAL study suggest that patients refractory to rituximab-containing regimens have inferior outcomes with HD-ASCT.

    Get Price
  • Efficacy of Axicabtagene Ciloleucel Compared to Standard

    Jan 05 2018 · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Biological Axicabtagene Ciloleucel Drug Platinum-containing salvage chemotherapy (eg R-ICE) followed by high dose therapy (eg BEAM) and autologous stem cell transplant in responders. Drug Cyclophosphamide Drug Fludarabine Phase 3

    Get Price

Products News

  • no 3 july 2012
  • rechercher les fabricants des ciment réfractaire moulable
  • rp graphite electrode graphite electrodes for sale
  • a data driven approach to environmental social and governance
  • frigidaire drum felt seals
  • electric steelmaking plants
  • microstructure and properties of sulfoaluminate cement
  • lowe s glass cutting servicedoes lowes cut custom glass
  • acers partnersbranches of ceramics the american ceramicrefractory supplies advanced ceramics crucible
  • fire resistant fabric
  • witt lining systems we can line anything

Product Center

  • Alumina Hollow Ball Bricks
  • Corundum Spinel Castable
  • High Alumina Refractory Cement
  • High Alumina Low Cement Castable
  • High Alumina Refractory Ramming Mass
  • Trough Refractory Castable
  • Magnesium Iron Spinel Brick
  • Mullite Brick
  • Zirconium Mullite Brick

Hot Products

  • Light Weight Silica Insulation Brick
  • Zirconia Hollow Sphere Brick
  • Corundum Refractory Castable
  • Heavy Alkali Resistant Castable
  • High Alumina Low Cement Castable
  • High Alumina Self Flowing Castable
  • Micro Expansion Refractory Plastic
  • Phosphate Refractory Mud
  • Magnesia Zircon Brick

Images Show

About Us

Rongsheng's main products are various types of unshaped refractory products, which are widely used in metallurgy, nonferrous metals, building materials, electric power, petrochemical and other industries.

Rongsheng pays attention to technological innovation and product research and development, and has established close cooperative relations with many universities and scientific research institutes.

Zhengzhou Rongsheng Company © Copyrights. Sitemap